Clinical trial · Observational
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for * Surgical resection + perioperative chemotherapy (cohort 1) * Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2) * Definitive chemoradiotherapy with curative intent (cohort 3) * Systemic therapy with the intent to prolong survival (cohort 4) * Palliative treatment without the use of chemotherapy (cohort 5)
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating tumor DNA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Cohort 1: Surgical resection + perioperative chemotherapy
- interventionNames
- Diagnostic Test: Circulating tumor DNA
- label
- Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery
- interventionNames
- Diagnostic Test: Circulating tumor DNA
- label
- Cohort 3: Definitive chemoradiotherapy
- interventionNames
- Diagnostic Test: Circulating tumor DNA
- label
- Cohort 4: Chemotherapy with the aim to prolong life expectancy
- interventionNames
- Diagnostic Test: Circulating tumor DNA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Gastroesophageal cancer Age 18 years or older Able to understand and sign written informed consent Exclusion Criteria: Patients not providing informed consent
References
Publications (0)
Data not yet available